Search

Retapamulin

Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.

Ponesimod

Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. … [A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709]

Poloxamer 188

P188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217]. … The ability of P188 in attenuating membrane damage and cell injury has been demonstrated in a variety of _in vivo_ and _in vitro_ models [A27218].

Technetium Tc-99m exametazime

It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease. … Technetium Tc-99m exametazime is a radiopharmaceutical sold under the trade name Ceretec used in the detection of altered regional cerebral perfusion in stroke and other cerebrovascular diseases.

Menotropins

It is used as a fertility medication that is injected either subcutaneously or intramuscularly. … It is composed of LH with 2 subunits, alpha = 92 residues, beta = 121 residues and FSH with 2 subunits, alpha = 92 residues, beta=111 residues.

Acetohydroxamic acid

Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.

Teprotumumab

[L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was … approved by the FDA in January 2020 for the treatment of TED.

Siponimod

It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … [L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]

Asparaginase Escherichia coli

Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia … It is available as intramuscular or intravenous injections.

RG-7795